Indole Antagonists for p53-Mdm2 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule drug discovery for protein-protein interactions, specifically the p53-Mdm2 complex, faces challenges due to the complex and flat interfaces, limiting the effectiveness of existing small molecule antagonists in disrupting the interaction effectively.
Innovation Solution
Development of novel small-molecule antagonists conforming to Formulae I and II, which include specifically designed indole derivatives synthesized using the Ugi multicomponent reaction, enhancing binding affinity through hydrophobic interactions and hydrogen bonding, and optimizing substituents for improved potency and solubility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecules are used to disrupt p53-Mdm2 interaction, then cancer cell apoptosis can be induced, but the flat and extended interface of the protein-protein interaction reduces binding affinity and potency
Solution Approach 1:
The patent segments the binding site into distinct hydrophobic and hydrogen-bonding regions, designing molecules that occupy specific sub-sites within the p53-Mdm2 interface. This segmentation allows small molecules to achieve high binding affinity despite the overall flat interface by focusing on localized high-value binding regions.
Solution Approach 2:
The patent applies local quality by creating molecules with specific functional groups positioned to interact with particular regions of the interface. The design incorporates hydrophobic aromatic rings for hydrophobic interactions and hydrogen-bonding capabilities at specific locations, optimizing binding at critical interface points rather than requiring uniform interaction across the entire interface.
2Reliability
If existing small molecule antagonists are used, then p53-Mdm2 interaction can be disrupted, but only a few compounds achieve sufficient potency and structural characterization
Solution Approach 1:
The patent systematically varies molecular parameters including the substitution patterns on aromatic rings, the positioning of hydrogen-bonding groups, and the overall molecular size to optimize potency. This parameter change approach allows efficient exploration of the chemical space to identify compounds with sub-micromolar Ki values.
Solution Approach 2:
The patent employs composite molecular structures combining multiple functional elements: hydrophobic aromatic moieties, hydrogen-bonding groups, and linkers that position these elements optimally. This composite design approach enables the creation of potent antagonists by integrating the beneficial properties of different molecular fragments.
3Adaptability or versatility
If the p53-Mdm2 interface is targeted for drug discovery, then cancer treatment potential is achieved, but the extended and flat interface makes it challenging for small molecule binding
Solution Approach 1:
The patent addresses the flat interface by designing molecules that extend in multiple dimensions relative to the interface plane. The aromatic rings and hydrogen-bonding groups are positioned to create three-dimensional interaction patterns that overcome the two-dimensional flat geometry of the p53-Mdm2 interface, enabling effective binding despite the extended interface characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel antagonists demonstrate enhanced binding affinity to Mdm2, with some compounds showing sub-micromolar inhibition constants, indicating potential as effective therapeutic agents for cancer treatment, particularly in relapsed/refractory leukemias and lymphomas.
Implementation Method 1
enhancing binding affinity through hydrophobic interactions and hydrogen bonding
Implementation Method 2
enhancing binding affinity through hydrophobic interactions and hydrogen bonding
Data Source
AI summary
Novel p53-Mdm2 antogonists that conform to Formula I or to Formula II:where the prescribed substituent groups are defined, are useful in treating or preventing cancer. In particular, the compounds and their pharmaceutical compositions are useful for treating relapsed/refractory acute myeloid and lymphoid leukemia and refractory chronic lymphocytic leukemia/small cell lymphocytic lymphomas.